Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.

Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S; Global Germ-Cell Cancer Group.

J Clin Oncol. 2019 Dec 26:JCO1901876. doi: 10.1200/JCO.19.01876. [Epub ahead of print]

PMID:
31877087
2.

The New Standard Adjuvant Treatment for High-risk Stage 1 Nonseminoma: Reducing the Treatment Burden and Maximizing Long-term Survival.

Tandstad T.

Eur Urol. 2020 Mar;77(3):352-353. doi: 10.1016/j.eururo.2019.12.010. Epub 2019 Dec 20. No abstract available.

PMID:
31870512
3.

Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study.

Kvammen Ø, Myklebust TÅ, Solberg A, Møller B, Klepp OH, Fosså SD, Tandstad T.

PLoS One. 2019 Dec 18;14(12):e0225942. doi: 10.1371/journal.pone.0225942. eCollection 2019.

4.

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.

Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS.

Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32704. [Epub ahead of print]

PMID:
31597192
5.

Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.

Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Andreassen KE, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A.

Eur Urol Oncol. 2019 Sep 8. pii: S2588-9311(19)30128-2. doi: 10.1016/j.euo.2019.08.002. [Epub ahead of print]

PMID:
31506250
6.

Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy.

Elschot M, Selnæs KM, Langørgen S, Johansen H, Bertilsson H, Tandstad T, Bathen TF.

PET Clin. 2019 Oct;14(4):487-498. doi: 10.1016/j.cpet.2019.06.003. Epub 2019 Aug 2. Review.

7.

Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study.

Al-Jebari Y, Glimelius I, Berglund Nord C, Cohn-Cedermark G, Ståhl O, Tandstad T, Jensen A, Sagstuen Haugnes H, Daugaard G, Rylander L, Giwercman A.

PLoS Med. 2019 Jun 4;16(6):e1002816. doi: 10.1371/journal.pmed.1002816. eCollection 2019 Jun.

8.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

9.

Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA.

Langberg MK, Berglund-Nord C, Cohn-Cedermark G, Haugnes HS, Tandstad T, Langberg CW.

Acta Oncol. 2018 Oct;57(10):1401-1406. doi: 10.1080/0284186X.2018.1479072. Epub 2018 Jun 5.

PMID:
29869895
10.

Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS.

Acta Oncol. 2018 Oct;57(10):1392-1400. doi: 10.1080/0284186X.2018.1473641. Epub 2018 May 18.

PMID:
29775128
11.

Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary.

Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, Nicolai N, Nichols C.

Eur Urol. 2018 Jun;73(6):899-907. doi: 10.1016/j.eururo.2017.12.030. Epub 2018 Jan 12. Review.

PMID:
29338978
12.

Ten thousand attentive hours, rapid learning, dissemination of knowledge and the future of experience-based care in germ-cell tumors.

Nichols C, Tandstad T, Lowrance W, Daneshmand S.

Ann Oncol. 2018 Feb 1;29(2):289-290. doi: 10.1093/annonc/mdx779. No abstract available.

13.

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT, Hanna NH, Albany C, Foster R, Cedermark GC, Feldman DR, Powles T, Lewis MA, Grimison PS, Bank D, Porter C, Albers P, De Santis M, Srinivas S, Bosl GJ, Nichols CR.

J Clin Oncol. 2017 Nov 1;35(31):3525-3528. doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30. No abstract available.

14.

Metastatisk prostatakreft bør følges i spesialisthelsetjenesten.

Berg AS, Tandstad T.

Tidsskr Nor Laegeforen. 2017 Aug 21;137(14-15). doi: 10.4045/tidsskr.17.0578. Print 2017 Aug 22. Norwegian. No abstract available.

PMID:
28828790
Free Article
15.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S.

J Clin Oncol. 2017 Jan 10;35(2):194-200. Epub 2016 Nov 28. Erratum in: J Clin Oncol. 2017 Mar;35(7):812.

16.

Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.

Hjelle LV, Bremnes RM, Gundersen POM, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Haugnes HS.

Urol Oncol. 2016 Nov;34(11):487.e13-487.e20. doi: 10.1016/j.urolonc.2016.06.012. Epub 2016 Aug 11.

PMID:
27523611
17.

Reply to 'The challenge to one course carboplatin in seminoma clinical stage 1' by Dieckmann and Anheuser.

Tandstad T, Cohn-Cedermark G.

Ann Oncol. 2016 Sep;27(9):1809. doi: 10.1093/annonc/mdw207. Epub 2016 May 13. No abstract available.

18.

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).

Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G; SWENOTECA.

Ann Oncol. 2016 Jul;27(7):1299-304. doi: 10.1093/annonc/mdw164. Epub 2016 Apr 6.

19.

Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor.

Kvammen Ø, Myklebust TÅ, Solberg A, Møller B, Klepp OH, Fosså SD, Tandstad T.

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):773-9. doi: 10.1158/1055-9965.EPI-15-1153. Epub 2016 Feb 11.

20.

[Treatment for stage I-testicular cancer should be assessed individually].

Oldenburg J, Haugnes HS, Dahl O, Karlsdottir Å, Langberg CW, Klepp O, Solberg A, Tandstad T.

Tidsskr Nor Laegeforen. 2015 Aug 25;135(15):1340-1. doi: 10.4045/tidsskr.15.0544. eCollection 2015 Aug 25. Norwegian. No abstract available.

21.

Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors.

Sprauten M, Haugnes HS, Brydøy M, Kiserud C, Tandstad T, Bjøro T, Bjerner J, Cvancarova M, Fosså SD, Oldenburg J.

Ann Oncol. 2015 Oct;26(10):2133-40. doi: 10.1093/annonc/mdv328. Epub 2015 Aug 11.

22.

The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway.

Tandstad T, Ståhl O, Håkansson U, Wahlqvist R, Klepp O, Cavallin-Ståhl E, Cohn-Cedermark G; SWENOTECA.

Scand J Urol. 2016;50(1):9-13. doi: 10.3109/21681805.2015.1059360. Epub 2015 Jun 26.

PMID:
26116316
23.

Primum Non Nocere: What Hurts in Clinical Stage I Testicular Cancer?

Tandstad T, Cohn-Cedermark G.

J Clin Oncol. 2015 Jul 10;33(20):2318-9. doi: 10.1200/JCO.2015.61.1152. Epub 2015 Jun 1. No abstract available.

PMID:
26033808
24.

Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.

Hjelle LV, Gundersen PO, Oldenburg J, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Bremnes RM, Haugnes HS.

Anticancer Res. 2015 Mar;35(3):1619-25.

PMID:
25750319
25.

Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?

Oldenburg J, Cullen M, Tandstad T.

Ann Oncol. 2015 Feb;26(2):255-6. doi: 10.1093/annonc/mdu520. Epub 2014 Nov 13. No abstract available.

26.

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.

Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruš D, Rosti G, Stephenson AJ, Tandstad T; On behalf of: SWENOTECA (Swedish Norwegian Testicular Cancer group), the Italian Germ Cell Cancer Group (IGG), Spanish Germ Cell Cancer Group (SGCCG).

Ann Oncol. 2015 May;26(5):833-8. doi: 10.1093/annonc/mdu514. Epub 2014 Nov 6. Review.

27.

Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.

Cohn-Cedermark G, Stahl O, Tandstad T; SWENOTECA.

Andrology. 2015 Jan;3(1):102-10. doi: 10.1111/andr.280. Epub 2014 Oct 1. Review.

28.

Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.

Tandstad T, Solberg A, Håkansson U, Stahl O, Haugnes HS, Oldenburg J, Dahl O, Kjellman A, Angelsen A, Cohn-Cedermark G; SWENOTECA.

Acta Oncol. 2015 Apr;54(4):493-9. doi: 10.3109/0284186X.2014.953256. Epub 2014 Sep 5.

PMID:
25192551
29.

Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.

Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, Protheroe A, Tyldesley S, Black PC, Chi K, So AI, Moore MJ, Nichols CR.

J Clin Oncol. 2015 Jan 1;33(1):51-7. doi: 10.1200/JCO.2014.56.2116. Epub 2014 Aug 18.

PMID:
25135991
30.

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.

Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G; SWENOTECA.

Ann Oncol. 2014 Nov;25(11):2167-72. doi: 10.1093/annonc/mdu375. Epub 2014 Aug 11.

31.

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C.

Ann Oncol. 2013 Apr;24(4):878-88. doi: 10.1093/annonc/mds579. Epub 2012 Nov 14.

32.

Testicular cancer and the tuberous sclerosis complex.

Tandstad T, Indrebø G.

Acta Oncol. 2012 Feb;51(2):262-5. doi: 10.3109/0284186X.2011.587450. Epub 2011 Jul 18. No abstract available.

PMID:
21767201
33.

Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.

Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E.

J Clin Oncol. 2011 May 20;29(15):2032-9. doi: 10.1200/JCO.2010.29.1278. Epub 2011 Apr 11.

PMID:
21482994
34.

Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.

Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G.

J Clin Oncol. 2011 Feb 20;29(6):719-25. doi: 10.1200/JCO.2010.30.1044. Epub 2011 Jan 4.

PMID:
21205748
35.

Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.

Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O.

Ann Oncol. 2010 Sep;21(9):1858-63. doi: 10.1093/annonc/mdq026. Epub 2010 Feb 8.

36.

Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O.

J Clin Oncol. 2009 May 1;27(13):2122-8. doi: 10.1200/JCO.2008.18.8953. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3263. J Clin Oncol. 2010 Mar 10;28(8):1438. Dosage error in article text.

PMID:
19307506

Supplemental Content

Loading ...
Support Center